GenomedWAR:GEN +14.17%74 Days Inventory is 63.43 as of Mar. 2026, which is 5% below its 10-year median of 66.78. GuruFocus rates WAR:GEN with a GF Score™ of 74/100 and a GF Value™ of zł37.88 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 177 Medical Diagnostics & Research companies, Genomed ranks better than 50.85% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Genomed's Average Total Inventories for the
three
months ended in Mar. 2026 was zł1.88 Mil. Genomed's Cost of Goods Sold for the
three
months ended in Mar. 2026 was zł2.71 Mil.
Hence, Genomed's Days Inventory for the
three
months ended in Mar. 2026 was 63.43.
The historical rank and industry rank for Genomed's Days Inventory or its related term are showing as below:
WAR:GEN'
s Days Inventory Range Over the Past 10 Years
Min: 46.44 Med: 66.78 Max: 89.07
Current: 66.29
During the past 13 years, Genomed's highest Days Inventory was 89.07. The lowest was 46.44. And the median was 66.78.
WAR:GEN's Days Inventory is ranked better than 50.85% of 177
companies
in the Medical Diagnostics & Research industry
Industry Median: 70.8
vs WAR:GEN: 66.29
Genomed's Days Inventory
declined
from Mar. 2025 (70.86) to Mar. 2026 (63.43).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Genomed's Inventory Turnover for the
three
months ended in Mar. 2026 was 1.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genomed's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.28.
Genomed (WAR:GEN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Genomed's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genomed's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Genomed Days Inventory Related Terms
Genomed Days Inventory Historical Data
* Premium members only.
The historical data trend for Genomed's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:GEN vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Genomed's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomed Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's Days Inventory distribution charts can be found below:
* The bar in red indicates where Genomed's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomed (WAR:GEN) has a Days Inventory of 63.43 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genomed and its competitors. This is near median its historical median of 66.78. Over the past decade, Genomed's Days Inventory has ranged from 46.44 to 89.07. According to the industry distribution chart, Genomed ranks #87 out of 177 companies in the Medical Diagnostics & Research industry, placing it in the top 49.2%.
Is Genomed's Days Inventory too high?
Genomed's current Days Inventory of 63.43 is near median its 10-year median of 66.78. Over the past 10 years, this metric has ranged from a low of 46.44 to a high of 89.07. The Medical Diagnostics & Research industry median Days Inventory is 70.80. Genomed's value of 63.43 is 10.4% below this industry median. Based on the distribution chart, Genomed ranks #87 out of 177 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genomed has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genomed ranks #87 out of 177 companies for Days Inventory. This puts Genomed in the upper half of its industry. The industry median Days Inventory is 70.80. Genomed's value of 63.43 is 10.4% below this benchmark. Historically, Genomed's own Days Inventory has ranged from 46.44 to 89.07 over the past decade. While the company's 10-year median is 66.78 vs. the industry median of 70.80, Genomed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 70.80, based on 177 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomed's current Days Inventory of 63.43 is 10.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Genomed and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 70.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomed's current Days Inventory is 63.43, which is near median its own 10-year median of 66.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł37.88, compared to a current price of zł29.00 — trading 23.4% below its estimated fair value. The current Days Inventory is 63.43, which is near median its 10-year median of 66.78 and 10.4% below the Medical Diagnostics & Research industry median of 70.80. Genomed's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Days Inventory is 63.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomed (WAR:GEN) Overvalued in 2026?
Based on GuruFocus' analysis, Genomed stock appears to be undervalued.
The current stock price of zł29.00 is trading 23.4% below its estimated GF Value™ of zł37.88.
GuruFocus considers Genomed to be Modestly Undervalued.
Key valuation signals for WAR:GEN:
Days Inventory: 63.43 (near median its 10-year median of 66.78)
GF Value™: zł37.88 vs. price of zł29.00 (23.4% below fair value)
Industry Position: 10.4% below the Medical Diagnostics & Research median (#87 of 177)
No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
74GF Score
Get the complete analysis for WAR:GEN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GEN has been successfully added to your 
